LOS ANGELES--(BUSINESS WIRE)--
ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC)
today announced that John Yu, MD, Founder and Chief Scientific Officer
of ImmunoCellular, will present a corporate overview and business update
at the BioCentury NewsMakers in the Biotech Industry Conference onFriday, September 27, 2013 at 2:30 p.m. ET at the Millennium Broadway
Hotel in New York City.
To access the live audio webcast of the BioCentury NewsMakers
presentation, please log on through a link located in the Investors
section of ImmunoCellular’s website at www.imuc.com,
under the Events & Presentations tab. A replay of the webcast will be
available one hour after the conclusion of the live event.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage
company that is developing immune-based therapies for the treatment of
brain and other cancers. ImmunoCellular is conducting a Phase II trial
of its lead product candidate, ICT-107, a dendritic cell-based vaccine
targeting multiple tumor-associated antigens for glioblastoma.
ImmunoCellular’s pipeline also includes ICT-121, a dendritic cell
vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting
ovarian cancer antigens and cancer stem cells. To learn more about
ImmunoCellular, please visit www.imuc.com.
For ImmunoCellular Therapeutics, Ltd.
Jane Green, 415-348-0010
Source: ImmunoCellular Therapeutics, Ltd.